̽»¨Ö±²¥

̽»¨Ö±²¥ announces launch of Aviation Impact Accelerator (AIA) – a team of experts in aerospace, economics, policy, and climate science, who are building an interactive simulator to help achieve net zero flight.

̽»¨Ö±²¥city’s West Cambridge site will be transformed into a dynamic Innovation District, connecting world-class researchers with world-class businesses, creating thousands of jobs and providing a ‘sense of place’ and amenities for residents. 

Connect: Health Tech, the ̽»¨Ö±²¥ of Cambridge Enterprise Zone, has today launched a roadmap, ‘Creating a ̽»¨Ö±²¥ Enterprise Zone for Cambridge across the life and physical sciences’, that examines the challenges faced in futureproofing and sustaining the growth of the life sciences cluster to maintain Cambridge as a global centre of excellence for health tech.

Formula 1 is to fund an undergraduate student from an underrepresented background to study for an engineering degree at the ̽»¨Ö±²¥ of Cambridge. ̽»¨Ö±²¥scholarship will be administered by the Cambridge Trust and will cover tuition fees and maintenance costs for the four year duration of the course.

̽»¨Ö±²¥Trinity Challenge has announced the winners of its inaugural competition, and is investing a £5.7 million (US$8 million) charitable pledged prize fund into one grand prize winner, two 2nd prize winners, and five 3rd prize winners.

Pioneering collaboration initiated by the ̽»¨Ö±²¥ of Cambridge, Imperial College London and ̽»¨Ö±²¥ College London

̽»¨Ö±²¥problem with being a futurist, says Richard Watson, is that change is happening a lot faster and a lot crazier these days. We talk to him about his recent work with the Entrepreneurship Centre and why thinking about a ‘preferred’ future is a good thing.

Researchers have created a plant-based, sustainable, scalable material that could replace single-use plastics in many consumer products.

̽»¨Ö±²¥so-called ‘bullshit jobs theory’ – which argues that a large and rapidly increasing number of workers are undertaking jobs that they themselves recognise as being useless and of no social value – contains several major flaws, argue researchers from the universities of Cambridge and Birmingham.

Three companies, Astex Pharmaceuticals, Eisai Ltd and Eli Lilly and Company, are joining forces with research scientists across Cambridge to explore promising new approaches to the treatment of neurodegenerative disease.